• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过量子点对总 HER2 负荷进行定量检测,并鉴定出一种具有不同 5 年预后的新亚型乳腺癌。

The quantitative detection of total HER2 load by quantum dots and the identification of a new subtype of breast cancer with different 5-year prognosis.

机构信息

Department of Oncology, Zhongnan Hospital of Wuhan University, No 169 Donghu Road, Wuchang District, Wuhan 430071, PR China.

出版信息

Biomaterials. 2010 Nov;31(33):8818-25. doi: 10.1016/j.biomaterials.2010.07.091. Epub 2010 Aug 17.

DOI:10.1016/j.biomaterials.2010.07.091
PMID:20723971
Abstract

Accurate classification is fundamental for breast cancer (BC) personalized care. Current BC classification based on the either traditional morphological staging or molecular signatures seems inefficient to reveal the"true"behaviors of invasive BC evolution. An appropriate approach combining the macro- and micro-pathologic information might be more useful academically as well as clinically. Here we explore a holistic approach by integrating a key molecular prognostic indicator of BC, HER2, with quantitative determination using quantum dots (QDs)--based nanotechnology and spectral analysis, and a key macropathologic indicator, tumor size, resulting a new indicator, total HER2 load. This indicator might better reveal BC heterogeneity and new subtypes of BC with different 5-year disease-free survival compared with current methods, which could be helpful in formulating a more personalized targeted therapy for BC. Furthermore, this mode integrating macro- and micro-pathological indicators might help gain new insights into invasive BC biological behaviors.

摘要

准确的分类对于乳腺癌(BC)的个性化护理至关重要。目前基于传统形态学分期或分子特征的 BC 分类方法似乎无法有效揭示浸润性 BC 演进的“真实”行为。一种将宏观和微观病理信息相结合的适当方法,在学术和临床方面可能更有用。在这里,我们通过整合乳腺癌的一个关键分子预后指标 HER2 以及使用量子点(QDs)--基于纳米技术和光谱分析的定量测定,以及一个关键的宏观病理指标肿瘤大小,得到了一个新的指标,总 HER2 负荷。与目前的方法相比,这个指标可能更好地揭示了 BC 的异质性和不同 5 年无病生存率的新亚型,这有助于为 BC 制定更个性化的靶向治疗方案。此外,这种整合宏观和微观病理指标的模式可能有助于深入了解浸润性 BC 的生物学行为。

相似文献

1
The quantitative detection of total HER2 load by quantum dots and the identification of a new subtype of breast cancer with different 5-year prognosis.通过量子点对总 HER2 负荷进行定量检测,并鉴定出一种具有不同 5 年预后的新亚型乳腺癌。
Biomaterials. 2010 Nov;31(33):8818-25. doi: 10.1016/j.biomaterials.2010.07.091. Epub 2010 Aug 17.
2
Quantum dots-based molecular classification of breast cancer by quantitative spectroanalysis of hormone receptors and HER2.基于量子点的乳腺癌激素受体和 HER2 定量光谱分析的分子分类。
Biomaterials. 2011 Oct;32(30):7592-9. doi: 10.1016/j.biomaterials.2011.06.029. Epub 2011 Jul 13.
3
Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.鉴定人表皮生长因子受体 2 阳性乳腺癌的亚型可揭示预后相关的基因特征。
J Clin Oncol. 2010 Apr 10;28(11):1813-20. doi: 10.1200/JCO.2009.22.8775. Epub 2010 Mar 15.
4
Quantum-dot-based immunofluorescent imaging of HER2 and ER provides new insights into breast cancer heterogeneity.基于量子点的 HER2 和 ER 免疫荧光成像为乳腺癌异质性提供了新的见解。
Nanotechnology. 2010 Mar 5;21(9):095101. doi: 10.1088/0957-4484/21/9/095101. Epub 2010 Jan 29.
5
Quantum dots-based immunofluorescence technology for the quantitative determination of HER2 expression in breast cancer.基于量子点的免疫荧光技术用于定量测定乳腺癌中HER2的表达。
Biomaterials. 2009 May;30(15):2912-8. doi: 10.1016/j.biomaterials.2009.02.010. Epub 2009 Feb 28.
6
Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases.三阴性和 HER2 过表达型乳腺癌具有更高的颅内转移风险和更早的发生。
Eur J Cancer. 2009 Nov;45(16):2792-8. doi: 10.1016/j.ejca.2009.06.027. Epub 2009 Jul 28.
7
Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.肿瘤组织学类型和分期而非p53、Her2-neu或组织蛋白酶D的表达是乳腺癌患者独立的预后因素。
Anticancer Res. 2004 May-Jun;24(3b):2061-8.
8
[Clinical characteristics and prognosis of different subtypes of breast cancer].[乳腺癌不同亚型的临床特征与预后]
Zhonghua Zhong Liu Za Zhi. 2008 Jun;30(6):456-61.
9
Characterization of breast cancer subtypes by quantitative assessment of biological parameters: relationship with clinicopathological characteristics, biological features and prognosis.通过生物参数的定量评估对乳腺癌亚型进行特征分析:与临床病理特征、生物学特性及预后的关系
Eur J Obstet Gynecol Reprod Biol. 2008 Dec;141(2):147-52. doi: 10.1016/j.ejogrb.2008.07.021. Epub 2008 Sep 2.
10
Quantum dots-based double-color imaging of HER2 positive breast cancer invasion.基于量子点的 HER2 阳性乳腺癌侵袭的双色成像。
Biochem Biophys Res Commun. 2011 Jun 10;409(3):577-82. doi: 10.1016/j.bbrc.2011.05.052. Epub 2011 May 15.

引用本文的文献

1
Quantum Dot Research in Breast Cancer: Challenges and Prospects.乳腺癌中的量子点研究:挑战与前景
Materials (Basel). 2024 May 4;17(9):2152. doi: 10.3390/ma17092152.
2
Computerized Assessment of the Tumor-stromal Ratio and Proposal of a Novel Nomogram for Predicting Survival in Invasive Breast Cancer.浸润性乳腺癌肿瘤-间质比的计算机评估及预测生存的新型列线图的提出
J Cancer. 2021 Apr 19;12(12):3427-3438. doi: 10.7150/jca.55750. eCollection 2021.
3
Tenascin-C immobilizes infiltrating T lymphocytes through CXCL12 promoting breast cancer progression.
Tenascin-C 通过 CXCL12 固定浸润的 T 淋巴细胞,促进乳腺癌进展。
EMBO Mol Med. 2021 Jun 7;13(6):e13270. doi: 10.15252/emmm.202013270. Epub 2021 May 14.
4
Prognostic Significance of the Tumor-Stromal Ratio in Invasive Breast Cancer and a Proposal of a New Ts-TNM Staging System.浸润性乳腺癌中肿瘤-间质比值的预后意义及一种新的Ts-TNM分期系统的提议
J Oncol. 2020 Apr 21;2020:9050631. doi: 10.1155/2020/9050631. eCollection 2020.
5
Single-Virus Tracking: From Imaging Methodologies to Virological Applications.单病毒追踪:从成像方法学到病毒学应用。
Chem Rev. 2020 Feb 12;120(3):1936-1979. doi: 10.1021/acs.chemrev.9b00692. Epub 2020 Jan 17.
6
Quantum Dot-Based Simultaneous Multicolor Imaging.基于量子点的同时多色成像。
Mol Imaging Biol. 2020 Aug;22(4):820-831. doi: 10.1007/s11307-019-01432-4.
7
Automated Quantification of Extranuclear ERα using Phosphor-integrated Dots for Predicting Endocrine Therapy Resistance in HR/HER2 Breast Cancer.利用磷集成点对核外雌激素受体α进行自动定量分析以预测HR/HER2乳腺癌的内分泌治疗耐药性
Cancers (Basel). 2019 Apr 12;11(4):526. doi: 10.3390/cancers11040526.
8
Incorporating gold nanoclusters and target-directed liposomes as a synergistic amplified colorimetric sensor for HER2-positive breast cancer cell detection.将金纳米簇和靶向脂质体结合作为一种用于检测HER2阳性乳腺癌细胞的协同放大比色传感器。
Theranostics. 2017 Feb 8;7(4):899-911. doi: 10.7150/thno.17927. eCollection 2017.
9
A Comparative Performance Analysis of Multispectral and RGB Imaging on HER2 Status Evaluation for the Prediction of Breast Cancer Prognosis.多光谱成像与RGB成像在评估HER2状态以预测乳腺癌预后方面的比较性能分析
Transl Oncol. 2016 Dec;9(6):521-530. doi: 10.1016/j.tranon.2016.09.007. Epub 2016 Nov 8.
10
Quantum dot-based molecular imaging of cancer cell growth using a clone formation assay.基于量子点的克隆形成试验检测用于检测癌细胞生长的分子成像。
Mol Med Rep. 2016 Oct;14(4):3007-12. doi: 10.3892/mmr.2016.5632. Epub 2016 Aug 18.